Detalhe da pesquisa
1.
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
Cancer Sci
; 114(5): 2087-2097, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36704833
2.
Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant.
Eur J Clin Pharmacol
; 78(4): 613-621, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35039908
3.
Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report.
Int J Clin Pharmacol Ther
; 59(4): 328-332, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355084
4.
Efficacy and safety of osimertinib in a Japanese compassionate use program.
Jpn J Clin Oncol
; 47(7): 625-629, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419328
5.
Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study.
BMJ Open
; 14(2): e076575, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417963
6.
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
J Thorac Oncol
; 17(10): 1227-1232, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788404
7.
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study.
Front Oncol
; 11: 770268, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34820333
8.
Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study.
Front Oncol
; 11: 618570, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34123782
9.
Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study.
J Cancer
; 12(7): 2105-2112, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33754009